Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03901079
Other study ID # S2362
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date October 8, 2018
Est. completion date March 24, 2021

Study information

Verified date December 2023
Source Boston Scientific Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To assess the safety and efficacy of the BridgePoint CTO system in recanalization of CTO lesions which are resistant to a conventional wire approach in a multicenter study in Chinese population


Description:

All subjects who are candidates for percutaneous coronary intervention (PCI), signed the informed consent form and had chronic total coronary occlusion (CTO) lesion will be evaluated for enrollment in this study.At least 100 subjects will be enrolled. Each site will be allowed to enroll up to a maximum of 25 subjects. Primary Effectiveness Endpoint: Technical Success: the ability of the BridgePoint Medical System to successfully facilitate placement of a guidewire beyond a CTO lesion in the true vessel lumen/within the collaterals in those cases that were otherwise refractory to treatment with a currently marketed guidewire Primary Safety Endpoint: 30-day MACE rate for CTO cases in which the BridgePoint Medical System was used. MACE is defined as the composite of cardiac death, Q-wave and non-Q-wave myocardial infarction(MI), and any ischemia-driven target lesion revascularization(TLR).


Recruitment information / eligibility

Status Terminated
Enrollment 20
Est. completion date March 24, 2021
Est. primary completion date January 10, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Subject must be = 18 but < 80 years of age - Subject (or legal guardian) understands the trial requirements and the treatment procedures and provides written informed consent before any trial-specific tests or procedures are performed - Subject is eligible for percutaneous coronary intervention (PCI) - Subject has symptomatic coronary artery disease or myocardial infraction (MI) with objective evidence of ischemia or silent ischemia - Subject is an acceptable candidate for coronary artery bypass grafting (CABG) - Subject is willing to comply with all protocol-required follow-up evaluation - Subject has a left ventricular ejection fraction (LVEF) =45% as measured within 60 days prior to enrollment Angiographic Inclusion Criteria: AI1. A maximum of one de novo CTO lesion in a native coronary artery with thrombolysis in Myocardial Infarction (TIMI) flow grade 0 AI2. Non-acute CTO lesion with an estimated duration of at least 3 months by clinical history and/or comparison with previous angiogram or electrocardiogram(ECG) AI3. The CTO lesion must have an angiographic landing zone= 10 mm proximal to any major bifurcation without severe calcification. AI4. Lesion length < 40mm without excessive tortuosity and angulation(>45°) Exclusion Criteria: - Subject has clinical symptoms and/or ECG changes consistent with Acute MI (include STEMI and Non- STEMI) within 1 week - Subject has cardiogenic shock, hemodynamic instability requiring inotropic or mechanical circulatory support, intractable ventricular arrhythmias, or ongoing intractable angina - Subject has received an organ transplant or is on a waiting list for an organ transplant - Subject is receiving or scheduled to receive chemotherapy within 30 days before or after the index procedure - Planned PCI (including staged procedures) or CABG after the index procedure - Subject has a known allergy to contrast (that cannot be adequately pre-medicated) and/or protocol-required concomitant medications (e.g., aspirin or all thienopyridines) - Subject has one of the following (as assessed prior to the index procedure): Other serious medical illness (e.g., cancer, congestive heart failure) with estimated life expectancy of less than 12 months / Current problems with substance abuse (e.g., alcohol, cocaine, heroin, etc.) / Planned procedure that may cause non-compliance with the protocol or confound data interpretation - Subject is receiving chronic (=72 hours) anticoagulation therapy (i.e., heparin, coumadin) - Subject with out of range complete blood count (CBC) values that are determined by the study physician to be clinically significant. - Subject is on dialysis or has baseline serum creatinine level >2.0 mg/dL (177µmol/L) - Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions - Subject has had a history of cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months - Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding - Subject has signs or symptoms of active heart failure (i.e., NYHA class IV) or LVEF < 45% at the time of the index procedure - Subject is participating in another investigational drug or device clinical trial that has not reached its primary endpoint or intends to participate in another investigational drug or device clinical trial within 12 months after the index procedure - Subject had PCI within the previous 2 weeks - Subject with known intention to procreate within 12 months after the index procedure (women of child-bearing potential who are sexually active must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure) - Subject is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential) Angiographic Exclusion Criteria: AE1. Target lesion is an aorto-ostial lesion or located in left main coronary artery, previous venous or arterial bypass grafts AE2. Target lesion involving a segment of previous stent AE3. Target vessel has excessive tortuosity and/or angulation proximal to the target lesion(>45°) AE4. Target lesion and/or the target vessel proximal to the target lesion is moderately to severely calcified by visual estimate AE5. Target lesion is located within 5 mm of the origin of the left anterior descending (LAD) coronary artery or left circumflex (LCx) coronary artery by visual estimate AE6. Target lesion will be accessed via a saphenous vein graft or arterial graft AE7. Subject has unprotected left main coronary artery disease (>50% diameter stenosis) AE8. Thrombus, or possible thrombus, present in the target vessel (by visual estimate) AE9. Target vessel has a dissection greater than National Heart, Lung, Blood Institute (NHLBI) type C

Study Design


Related Conditions & MeSH terms


Intervention

Other:
single-arm study
single-arm study

Locations

Country Name City State
China West China Hospital Sichuan University Chengdu Sichuan

Sponsors (1)

Lead Sponsor Collaborator
Boston Scientific Corporation

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Technical Success: Successfully Facilitate Placement of a Guidewire Beyond a CTO Lesion in the True Vessel Lumen/Within the Collaterals 6 subjects have the results data, and 5 of them (83.3%) reported technical success. One (16.7%) failed. Subject follow up will occur via telephone contact or clinic visit at 30 days,6 and 12 months post index procedure.
See also
  Status Clinical Trial Phase
Terminated NCT04459299 - CorPath GRX STEMI Study
Not yet recruiting NCT02853994 - Safety and Efficacy of the DEVOIR Sirolimus-Coated Coronary Balloon in the Real-world Clinical Practice N/A
Completed NCT02440893 - Understanding the Effect of Metformin on Corus CAD (or ASGES)
Completed NCT01486030 - Effect of Exercise Stress Testing on Peripheral Gene Expression Using Corus CAD (or ASGES) Diagnostic Test
Recruiting NCT06239493 - IVUS-Guided Treatment for Percutaneous Vascular Interventions
Recruiting NCT05344612 - Comparing a Diagnostic and Treatment Strategy of Upfront CTCA With SOC in Patients With Chest Pain and Suspected CAD N/A
Completed NCT02457455 - Urgent Medical and Surgical Conditions During Flights N/A
Recruiting NCT05509010 - AI Driven National Platform for CT cOronary Angiography for clinicaL and industriaL applicatiOns Registry
Completed NCT03930589 - Remote Ischemic Conditioning in STEMI to Decrease Infarct Size N/A
Completed NCT01251302 - Utility of a Molecular Personalized Coronary Gene Expression Test (Corus CAD or ASGES) on Cardiology Practice Pattern
Withdrawn NCT02158754 - Clinician Utilization of Corus CAD (or ASGES) in Primary Care Provider Decision Making
Completed NCT01949844 - Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies N/A
Recruiting NCT04787796 - The Application of a Portable Multichannel ECG System for the Patients Suspected to Have Possible CAD or ACS N/A
Recruiting NCT03894423 - Comprehensive Computed Tomography Guidance of Coronary Bypass Graft Surgery
Completed NCT02223286 - Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making N/A
Completed NCT06154018 - Heparin Reversal With Two Different Protamine Ratios After Cardiopulmonary By-pass. N/A
Completed NCT02132611 - Coronary Orbital Atherectomy System Study N/A
Completed NCT01406990 - Aspirin Responsiveness in Women With Coronary Artery Disease N/A
Completed NCT01402804 - NSAIDs in Coronary Artery Disease Patients N/A
Completed NCT00500617 - Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree